Pathology for NEET-PG
Neoplasia and Tumour Markers for NEET-PG
Neoplasia covers the biology of cancer from mutation to metastasis, and tumour markers connect that biology to clinical monitoring, making this a high-yield NEET-PG pairing. The topic explains oncogenes and tumour suppressor genes, the hallmarks of malignancy, routes of spread, and the serum markers used to screen, monitor, and follow specific cancers. Marker questions are frequently one-liners that name a marker and ask for the associated tumour, so the marker-tumour map is the essential deliverable. Examiners emphasise the difference between benign and malignant features, the classic gene mutations linked to named cancers, tumour grading versus staging, and paraneoplastic syndromes. The topic links to general medicine, surgery, and obstetrics. Common traps include treating tumour markers as diagnostic when most are for monitoring, confusing grading with staging, and mixing up the specific oncogene or suppressor gene tied to a syndrome. Anchoring each marker and gene to a memorable cancer keeps this block fast to recall.
MedNext Academy | 3 min read
Neoplasia and Tumour Markers for NEET-PG
Neoplasia covers the biology of cancer from mutation to metastasis, and tumour markers connect that biology to clinical monitoring, making this a high-yield NEET-PG pairing. The topic explains oncogenes and tumour suppressor genes, the hallmarks of malignancy, routes of spread, and the serum markers used to screen, monitor, and follow specific cancers. Marker questions are frequently one-liners that name a marker and ask for the associated tumour, so the marker-tumour map is the essential deliverable. Examiners emphasise the difference between benign and malignant features, the classic gene mutations linked to named cancers, tumour grading versus staging, and paraneoplastic syndromes. The topic links to general medicine, surgery, and obstetrics. Common traps include treating tumour markers as diagnostic when most are for monitoring, confusing grading with staging, and mixing up the specific oncogene or suppressor gene tied to a syndrome. Anchoring each marker and gene to a memorable cancer keeps this block fast to recall.
Neoplasia covers the biology of cancer from mutation to metastasis, and tumour markers connect that biology to clinical monitoring, making this a high-yield NEET-PG pairing. The topic explains oncogenes and tumour suppressor genes, the hallmarks of malignancy, routes of spread, and the serum markers used to screen, monitor, and follow specific cancers. Marker questions are frequently one-liners that name a marker and ask for the associated tumour, so the marker-tumour map is the essential deliverable. Examiners emphasise the difference between benign and malignant features, the classic gene mutations linked to named cancers, tumour grading versus staging, and paraneoplastic syndromes. The topic links to general medicine, surgery, and obstetrics. Common traps include treating tumour markers as diagnostic when most are for monitoring, confusing grading with staging, and mixing up the specific oncogene or suppressor gene tied to a syndrome. Anchoring each marker and gene to a memorable cancer keeps this block fast to recall.
Key points
- **Oncogenes vs tumour suppressors:** Oncogenes such as RAS and MYC drive growth when activated; tumour suppressors such as TP53 and RB restrain it when functional and cause cancer when lost.
- **Grading vs staging:** Grading reflects cellular differentiation under the microscope; staging reflects tumour size, nodal spread, and metastasis, and staging matters more for prognosis.
- **Alpha-fetoprotein:** Raised in hepatocellular carcinoma and non-seminomatous germ cell tumours such as yolk sac tumour.
- **CA-125:** Used to monitor epithelial ovarian cancer; it is not reliable for screening because many benign conditions raise it.
- **CEA:** Carcinoembryonic antigen is used to monitor colorectal cancer recurrence, not for screening.
- **PSA:** Prostate-specific antigen aids prostate cancer detection and monitoring but is also raised in benign prostatic hyperplasia and prostatitis.
- **Beta-hCG:** Marker for gestational trophoblastic disease and germ cell tumours, and part of testicular tumour follow-up.
- **Paraneoplastic syndromes:** Small cell lung cancer causes SIADH and ectopic ACTH; squamous cell lung cancer causes hypercalcaemia via PTH-related peptide.
- **Metastasis routes:** Carcinomas spread mainly by lymphatics, sarcomas mainly by blood; certain cancers show organ tropism such as breast to bone.
- **Hallmarks of malignancy:** Sustained proliferation, evasion of apoptosis, angiogenesis, invasion, and metastasis distinguish malignant from benign tumours.
- **Tumour suppressor syndromes:** APC in familial adenomatous polyposis, BRCA in breast and ovarian cancer, and RB in retinoblastoma are classic associations.
Frequently Asked Questions
Are tumour markers used to diagnose cancer?
Mostly no. Markers such as CEA, CA-125, and PSA are chiefly for monitoring treatment response and recurrence. They lack the specificity needed for standalone diagnosis.
What is the difference between grading and staging?
Grading describes how abnormal tumour cells look and how well they are differentiated. Staging describes how far the tumour has spread. Stage generally guides prognosis and treatment more strongly.
Which tumour marker goes with which cancer?
AFP with hepatocellular and yolk sac tumours, CA-125 with ovarian, CEA with colorectal, PSA with prostate, and beta-hCG with trophoblastic and germ cell tumours.
What are paraneoplastic syndromes?
Remote effects of a tumour mediated by hormones or immune responses rather than direct invasion, such as SIADH or hypercalcaemia with lung cancers.
Continue reading
NEET-PGComplete NEET-PG guide
Review the exam pattern, preparation and resources.
Practise Pathology for NEET-PG
Explore clinician-written learning resources, structured revision and practice across the MedNext platform.
See plans